RxDoctor Payments Data

Nabil Wehbe, DO

Internal Medicine · Novi, MINPI 1669452140

Payments from drug & device makers

$501in general payments, 2019–2025

Across 26 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$165
  • Medtronic$162
  • Novartis$29
  • Astellas Pharma US Inc$29
  • Lilly USA, LLC$26
  • Merck$23
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$501100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$501 in reported general payments places this provider in the 65th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$82,861
Medicare patients
214
Services billed
988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin89$124,586
EliquisApixaban81$101,487
JanuviaSitagliptin Phosphate55$69,568
MounjaroTirzepatide55$61,532
OzempicSemaglutide36$52,378
TrulicityDulaglutide36$50,925
FarxigaDapagliflozin Propanediol33$44,144
XareltoRivaroxaban27$30,163
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$21,554
Breo ElliptaFluticasone/Vilanterol27$13,658
Atorvastatin Calcium818$11,165
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$7,401
Metoprolol Succinate264$4,405
PaxlovidNirmatrelvir/Ritonavir14$4,210
Losartan Potassium303$3,778

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$26$112,45791 claims
MerckJanuvia$23$69,56855 claims
AstraZenecaFarxiga$165$44,14433 claims
AbbVieSynthroid$19$1,32915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Novi

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →